What is Amgen?
Headquartered in Thousand Oaks, California, Amgen Inc. (Nasdaq: AMGN) stands as a pioneer in the biotechnology industry. Since its inception in 1980 as Applied Molecular Genetics, the company has evolved into a multinational powerhouse, specializing in the discovery, development, and manufacturing of human therapeutics. By leveraging advanced molecular biology and biochemistry, Amgen addresses significant unmet medical needs in areas such as oncology, cardiovascular disease, and inflammation. Its market position is defined by a rigorous focus on scientific innovation and a highly scalable manufacturing infrastructure, allowing it to maintain a competitive edge in the global pharmaceutical landscape.
How much funding has Amgen raised?
Amgen has raised a total of $2B across 2 funding rounds:
Debt
$19M
Debt
$2B
Debt (1980): $19M, investors not publicly disclosed
Debt (2022): $2B led by Citi
Key Investors in Amgen
Citi
Citigroup is a global financial services institution providing a broad range of banking and financial solutions to individuals, corporations, governments, financial institutions, and other organizations worldwide.
Undisclosed Investors
Undisclosed Investors
What's next for Amgen?
With the infusion of capital from its recent strategic financing, Amgen is well-positioned to accelerate its R&D pipeline and pursue inorganic growth opportunities. The company is expected to prioritize the integration of next-generation therapeutic modalities, including multispecific antibodies and genetic medicine platforms. Furthermore, the firm will likely utilize these financial resources to optimize its global supply chain and expand its footprint in emerging markets. As the biotech sector faces increasing regulatory scrutiny and pricing pressures, Amgen's ability to deploy this capital effectively will be critical in sustaining its long-term growth trajectory and delivering value to shareholders through sustained clinical breakthroughs.
See full Amgen company page
